## Ivan Rychlik

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4428589/publications.pdf

Version: 2024-02-01

218381 128067 64 3,838 26 60 citations h-index g-index papers 66 66 66 5163 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. American Journal of Kidney Diseases, 1999, 34, 795-808.	2.1	703
2	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	6.3	408
3	Carnosine as a Protective Factor in Diabetic Nephropathy: Association With a Leucine Repeat of the Carnosinase Gene CNDP1. Diabetes, 2005, 54, 2320-2327.	0.3	264
4	Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrology Dialysis Transplantation, 2021, 36, 87-94.	0.4	259
5	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. Journal of the American Society of Nephrology: JASN, 2015, 26, 1999-2010.	3.0	205
6	Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 953-962.	3.0	203
7	The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. Nephrology Dialysis Transplantation, 2004, 19, 3040-3049.	0.4	187
8	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 301-312.	5.5	166
9	How to routinely collect data on patient-reported outcome and experience measures in renal registries in Europe: an expert consensus meeting. Nephrology Dialysis Transplantation, 2015, 30, 1605-1614.	0.4	121
10	Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy. PLoS ONE, 2010, 5, e13421.	1.1	117
11	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrology Dialysis Transplantation, 2014, 29, 1563-1570.	0.4	106
12	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open, 2016, 6, e010310.	0.8	103
13	Clinical Manifestation and Natural History of Diabetic Nephropathy. Contributions To Nephrology, 2011, 170, 19-27.	1.1	86
14	Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?. Scientific Reports, 2017, 7, 16915.	1.6	67
15	Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994–2011. Journal of Nephrology, 2015, 28, 39-49.	0.9	55
16	Urinary Collagen Fragments Are Significantly Altered in Diabetes: A Link to Pathophysiology. PLoS ONE, 2010, 5, e13051.	1.1	51
17	Composing a new song for trials: the Standardized Outcomes in Nephrology (SONG) initiative. Nephrology Dialysis Transplantation, 2017, 32, 1963-1966.	0.4	50
18	Osteoporosis and Impaired Trabecular Bone Score in Hemodialysis Patients. Kidney and Blood Pressure Research, 2016, 41, 345-354.	0.9	42

#	Article	IF	CITATIONS
19	NFκB and Its Inhibitor IκB in Relation to Type 2 Diabetes and Its Microvascular and Atherosclerotic Complications. Human Immunology, 2006, 67, 706-713.	1.2	38
20	Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria. International Journal of Endocrinology, 2013, 2013, 1-7.	0.6	38
21	Mild cognitive impairment and kidney disease: clinical aspects. Nephrology Dialysis Transplantation, 2020, 35, 10-17.	0.4	38
22	Repeat protocol renal biopsy in ANCA-associated renal vasculitis. Nephrology Dialysis Transplantation, 2014, 29, 1728-1732.	0.4	31
23	Polymorphisms in the Vitamin D Receptor Gene and Parathyroid Hormone Gene in the Development and Progression of Diabetes Mellitus and its Chronic Complications, Diabetic Nephropathy and Non-Diabetic Renal Disease. Kidney and Blood Pressure Research, 2012, 36, 1-9.	0.9	28
24	Ambulatory blood pressure monitoring: fancy gadgetry or clinically useful exercise?. Nephrology Dialysis Transplantation, 2001, 16, 1550-1554.	0.4	27
25	Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. Nephrology Dialysis Transplantation, 2019, 34, 1112-1114.	0.4	27
26	Transjugular Renal Biopsy. Kidney and Blood Pressure Research, 2001, 24, 207-212.	0.9	26
27	ERA-EDTA invests in transformation to greener health care. Nephrology Dialysis Transplantation, 2018, 33, 901-903.	0.4	21
28	Renal disease and acute coronary syndrome. Heart, 2010, 96, 86-92.	1.2	17
29	Cystatin C as a Marker of Residual Renal Function during Continuous Hemodiafiltration. Kidney and Blood Pressure Research, 2005, 28, 14-19.	0.9	14
30	Determination of Dialysis Dose: A Clinical Comparison of Methods. Blood Purification, 2011, 32, 271-277.	0.9	14
31	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. Nephrology Dialysis Transplantation, 2021, 37, ii14-ii23.	0.4	11
32	Daily hemodialysis and caregivers burden. Nephrology Dialysis Transplantation, 2011, 26, 2074-2076.	0.4	10
33	Predictors of bone fractures in a single-centre cohort of hemodialysis patients: a 2-year follow-up study. International Urology and Nephrology, 2018, 50, 1721-1728.	0.6	10
34	Nephrology: achieving sustainability. Nephrology Dialysis Transplantation, 2020, 35, 2030-2033.	0.4	10
35	A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney International, 2022, 101, 349-359.	2.6	10
36	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. CKJ: Clinical Kidney Journal, 2021, 14, 23-35.	1.4	10

#	Article	IF	CITATIONS
37	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. Nephrology Dialysis Transplantation, 2019, 34, 1469-1480.	0.4	8
38	LONG TERM TREATMENT OF IgA NEPHROPATHY WITH CYCLOSPORINE A. Renal Failure, 2000, 22, 55-62.	0.8	7
39	A snapshot of European registries on chronic kidney disease patients not on kidney replacement therapy. Nephrology Dialysis Transplantation, 2021, 37, 8-13.	0.4	7
40	Bioptically Proven "Anticoagulation-Related Nephropathy" Induced by Dual Antiplatelet Therapy. Case Reports in Nephrology and Dialysis, 2018, 8, 216-222.	0.3	6
41	Funding kidney research as a public health priority: challenges and opportunities. Nephrology Dialysis Transplantation, 2020, , .	0.4	6
42	Dyslipidemia in patients with chronic kidney disease: etiology and management. Vnitrni Lekarstvi, 2020, 66, 275-281.	0.1	6
43	Can Renal Parameters Predict the Mortality of Hospitalized COVID-19 Patients?. Kidney and Blood Pressure Research, 2022, 47, 309-319.	0.9	6
44	Prevalence and Risk of Hypertension in Renal Disease – Data from the Czech Registry of Renal Biopsies. Kidney and Blood Pressure Research, 2008, 31, 135-142.	0.9	5
45	The Intron 4 Polymorphism in the Calcium-Sensing Receptor Gene in Diabetes Mellitus and its Chronic Complications, Diabetic Nephropathy and Non-Diabetic Renal Disease. Kidney and Blood Pressure Research, 2014, 39, 399-407.	0.9	5
46	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. Nephrology Dialysis Transplantation, 2018, 33, 1077-1082.	0.4	4
47	FP129NEWLY ADMINISTERED IMMUNOSUPPRESSIVE THERAPY (IST) HAS NO IMPACT ON LONG-TERM ANTIPROTEINURIC EFFECT OF SPARSENTAN (SPAR), A DUAL ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): INTERIM ANALYSIS OF THE DUET TRIAL. Nephrology Dialysis Transplantation, 2018, 33, i20-i20.	0.4	4
48	<i>Lancet</i> Countdown paper: what does it mean for nephrology?. Nephrology Dialysis Transplantation, 2019, 34, 4-6.	0.4	4
49	Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study. Current Vascular Pharmacology, 2018, 16, 298-305.	0.8	3
50	Endstage renal failure in diabetes type II - a silent epidemic. Nephrology, 1998, 4, 299-302.	0.7	2
51	The nephrology crystal ball: the medium-term future. Nephrology Dialysis Transplantation, 2019, 35, 222-226.	0.4	2
52	Loss of bone mineral density and trabecular bone score in elderly hemodialysis patients: a 2-year follow-up, prospective, single-centre study. International Urology and Nephrology, 2020, 52, 379-385.	0.6	2
53	Improvement of atopic dermatitis and IgA nephropathy in a patient treated by dupilumab. Dermatologic Therapy, 2021, 34, e14708.	0.8	2
54	Obstructive Jaundice Secondary to Pancreatic Head Metastasis of Malignant Amelanotic Melanoma as the First Clinical Manifestation. Prague Medical Report, 2021, 122, 45-51.	0.4	2

#	Article	IF	CITATIONS
55	A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients. Metabolites, 2021, 11, 774.	1.3	2
56	The Influence of Pefloxacine on Experimental Adriamycin-Induced Nephrotic Syndrome in Rats. Renal Failure, 1996, 18, 195-199.	0.8	1
57	Diabetic Nephropathy—the Size of the Problem. , 0, , 1-17.		1
58	Biosimilars and Renal Health Care in the Countries of Central and Eastern Europe. Kidney and Blood Pressure Research, 2007, 30, 2-5.	0.9	1
59	Editorial. Kidney and Blood Pressure Research, 2011, 34, 202-202.	0.9	1
60	Contribution of Jan Brod to Nephrology. Kidney and Blood Pressure Research, 2011, 34, 299-302.	0.9	1
61	What Is the Quality of Pre-Dialysis Healthcare in the Czech Republic. Kidney and Blood Pressure Research, 2012, 35, 417-424.	0.9	1
62	Gene polymorphisms in patients with type 2 diabetes and diabetic nephropathy. Open Life Sciences, 2012, 7, 210-218.	0.6	1
63	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. CKJ: Clinical Kidney Journal, 2018, 11, 437-442.	1.4	1
64	Nephrology in the Czech Republic. , 2021, , 499-509.		0